Feasibility of Radiofrequency Ablation in the Management of Papillary Thyroid Cancer Under Ultra-Sound Guidance.
Recruitment status was Not yet recruiting
To study the feasibility of Radiofrequency ablation (RFA) via ultrasound guidance in the treatment of papillary thyroid cancer (PTC).
Papillary Thyroid Cancer
Procedure: Ultra-sound guided radio-frequency ablation
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Feasibility of Radio-Frequency Ablation in the Management of Papillary Thyroid Cancer Under Ultra-Sound Guidance|
- After the procedure, each patient will have his/her routine post-operative care and the follow up visits for surgery, without additional specified visits or procedures for the study
- Patients will be examined for any possible complications at the time of surgery.
- Patients will be followed-up accordingly for any complications.
|Study Start Date:||November 2006|
|Estimated Study Completion Date:||November 2008|
Around 23,000 cases of thyroid cancer are discovered annually in the US, and PTC accounts for 70-75% of those cases. The conventional treatment consists mainly of surgical resection, in the form of lobectomy with/without isthmusectomy, or total thyroidectomy, making it one of the most commonly performed procedures. It has high costs, and exposes the patients to morbidity of surgery and anesthesia. PTC tends to be indolent with a 90% cure rate and controversy exists regarding extent of treatment.
Percutaneous image-guided RFA has received increasing attention as a promising minimally invasive technique for the treatment of focal malignant disease. It permits the in situ destruction of tumors without necessitating their surgical excision.
|Contact: Tarik Farrag, M.Dfirstname.lastname@example.org|
|United States, Maryland|
|Johns Hopkins University, School of Medicine||Not yet recruiting|
|Baltimore, Maryland, United States, 21287|
|Principal Investigator:||Kieran Murphy, M.D||Johns Hopkins University|